APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroprotective Drugs Market Analysis and Forecast 2026-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchNeuroprotective Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroprotective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroprotective Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuroprotective Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroprotective Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroprotective Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroprotective Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neuroprotective Drugs include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Biogen, AstraZeneca, NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Genervon Biopharmaceuticals and Ceregene, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuroprotective Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroprotective Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Neuroprotective Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroprotective Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroprotective Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neuroprotective Drugs sales, projected growth trends, production technology, application and end-user industry.

Neuroprotective Drugs Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Biogen

AstraZeneca

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Genervon Biopharmaceuticals

Ceregene

Bionure

BHR Pharma

Allon therapeutics

Neuroprotective Drugs Segment by Type

Cholinesterase inhibitors

Anti-inflammatory

Others

Neuroprotective Drugs Segment by Application

Alzheimer's disease

Parkinson's disease

Others

Neuroprotective Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neuroprotective Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroprotective Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroprotective Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cholinesterase inhibitors Major Manufacturers Table 3. Anti-inflammatory Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Neuroprotective Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Alzheimer's disease Major Manufacturers Table 7. Parkinson's disease Major Manufacturers Table 8. Others Major Manufacturers Table 9. Neuroprotective Drugs Industry Trends Table 10. Neuroprotective Drugs Industry Drivers Table 11. Neuroprotective Drugs Industry Opportunities and Challenges Table 12. Neuroprotective Drugs Industry Restraints Table 13. Global Neuroprotective Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Neuroprotective Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Neuroprotective Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Neuroprotective Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Neuroprotective Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Neuroprotective Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (tons) Table 19. Global Neuroprotective Drugs Sales by Region (2021-2026) & (tons) Table 20. Global Neuroprotective Drugs Sales by Region (2027-2032) & (tons) Table 21. Global Neuroprotective Drugs Sales Market Share by Region (2021-2026) Table 22. Global Neuroprotective Drugs Sales Market Share by Region (2027-2032) Table 23. Global Neuroprotective Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Neuroprotective Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Neuroprotective Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Neuroprotective Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Neuroprotective Drugs Sales Price (US$/kg) of Manufacturers (2021-2026) Table 28. Global Neuroprotective Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Neuroprotective Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Neuroprotective Drugs Manufacturers, Product Type & Application Table 31. Global Neuroprotective Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Neuroprotective Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Neuroprotective Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Neuroprotective Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Neuroprotective Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Neuroprotective Drugs Sales by Type 2021 VS 2025 VS 2032 (tons) Table 40. Global Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 41. Global Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 42. Global Neuroprotective Drugs Sales Market Share by Type (2021-2026) Table 43. Global Neuroprotective Drugs Sales Market Share by Type (2027-2032) Table 44. Global Neuroprotective Drugs Price by Type (2021-2026) & (US$/kg) Table 45. Global Neuroprotective Drugs Price by Type (2027-2032) & (US$/kg) Table 46. Global Neuroprotective Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Neuroprotective Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Neuroprotective Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Neuroprotective Drugs Sales by Application 2021 VS 2025 VS 2032 (tons) Table 52. Global Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 53. Global Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 54. Global Neuroprotective Drugs Sales Market Share by Application (2021-2026) Table 55. Global Neuroprotective Drugs Sales Market Share by Application (2027-2032) Table 56. Global Neuroprotective Drugs Price by Application (2021-2026) & (US$/kg) Table 57. Global Neuroprotective Drugs Price by Application (2027-2032) & (US$/kg) Table 58. Teva Pharmaceutical Industries Ltd Company Information Table 59. Teva Pharmaceutical Industries Ltd Business Overview Table 60. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 61. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio Table 62. Teva Pharmaceutical Industries Ltd Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 66. Novartis Neuroprotective Drugs Product Portfolio Table 67. Novartis Recent Development Table 68. Merck KGaA Company Information Table 69. Merck KGaA Business Overview Table 70. Merck KGaA Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 71. Merck KGaA Neuroprotective Drugs Product Portfolio Table 72. Merck KGaA Recent Development Table 73. Biogen Company Information Table 74. Biogen Business Overview Table 75. Biogen Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 76. Biogen Neuroprotective Drugs Product Portfolio Table 77. Biogen Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 81. AstraZeneca Neuroprotective Drugs Product Portfolio Table 82. AstraZeneca Recent Development Table 83. NeuroVive Pharmaceutical Company Information Table 84. NeuroVive Pharmaceutical Business Overview Table 85. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 86. NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio Table 87. NeuroVive Pharmaceutical Recent Development Table 88. Neuren Pharmaceuticals Company Information Table 89. Neuren Pharmaceuticals Business Overview Table 90. Neuren Pharmaceuticals Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 91. Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio Table 92. Neuren Pharmaceuticals Recent Development Table 93. Genervon Biopharmaceuticals Company Information Table 94. Genervon Biopharmaceuticals Business Overview Table 95. Genervon Biopharmaceuticals Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 96. Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio Table 97. Genervon Biopharmaceuticals Recent Development Table 98. Ceregene Company Information Table 99. Ceregene Business Overview Table 100. Ceregene Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 101. Ceregene Neuroprotective Drugs Product Portfolio Table 102. Ceregene Recent Development Table 103. Bionure Company Information Table 104. Bionure Business Overview Table 105. Bionure Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 106. Bionure Neuroprotective Drugs Product Portfolio Table 107. Bionure Recent Development Table 108. BHR Pharma Company Information Table 109. BHR Pharma Business Overview Table 110. BHR Pharma Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 111. BHR Pharma Neuroprotective Drugs Product Portfolio Table 112. BHR Pharma Recent Development Table 113. Allon therapeutics Company Information Table 114. Allon therapeutics Business Overview Table 115. Allon therapeutics Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 116. Allon therapeutics Neuroprotective Drugs Product Portfolio Table 117. Allon therapeutics Recent Development Table 118. North America Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 119. North America Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 120. North America Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 121. North America Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 122. North America Neuroprotective Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 123. North America Neuroprotective Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 124. North America Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 127. North America Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 128. North America Neuroprotective Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 129. North America Neuroprotective Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 130. North America Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Neuroprotective Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. North America Neuroprotective Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. North America Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 134. North America Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 135. North America Neuroprotective Drugs Sales by Country (2027-2032) & (tons) Table 136. North America Neuroprotective Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 137. North America Neuroprotective Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 138. United States Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 139. Canada Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 140. Mexico Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 141. Europe Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. Europe Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. Europe Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 144. Europe Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 145. Europe Neuroprotective Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 146. Europe Neuroprotective Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 147. Europe Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 150. Europe Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 151. Europe Neuroprotective Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 152. Europe Neuroprotective Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 153. Europe Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Europe Neuroprotective Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 155. Europe Neuroprotective Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 156. Europe Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 157. Europe Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 158. Europe Neuroprotective Drugs Sales by Country (2027-2032) & (tons) Table 159. Europe Neuroprotective Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 160. Europe Neuroprotective Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 161. Germany Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 162. France Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 163. U.K. Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 164. Italy Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 165. Russia Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 166. Spain Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 167. Netherlands Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 168. Switzerland Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 169. Sweden Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 170. Poland Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 171. China Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 172. China Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 173. China Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 174. China Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 175. China Neuroprotective Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 176. China Neuroprotective Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 177. China Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 178. China Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 179. China Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 180. China Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 181. China Neuroprotective Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 182. China Neuroprotective Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 183. Asia Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 184. Asia Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 185. Asia Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 186. Asia Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 187. Asia Neuroprotective Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 188. Asia Neuroprotective Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 189. Asia Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 190. Asia Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 191. Asia Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 192. Asia Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 193. Asia Neuroprotective Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 194. Asia Neuroprotective Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 195. Asia Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. Asia Neuroprotective Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 197. Asia Neuroprotective Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 198. Asia Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 199. Asia Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 200. Asia Neuroprotective Drugs Sales by Country (2027-2032) & (tons) Table 201. Asia Neuroprotective Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 202. Asia Neuroprotective Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 203. Japan Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 204. South Korea Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 205. India Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 206. Australia Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 207. Taiwan Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 208. Southeast Asia Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 209. SAMEA Neuroprotective Drugs Revenue by Type (2021-2026) & (US$ Million) Table 210. SAMEA Neuroprotective Drugs Revenue by Type (2027-2032) & (US$ Million) Table 211. SAMEA Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 212. SAMEA Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 213. SAMEA Neuroprotective Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 214. SAMEA Neuroprotective Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 215. SAMEA Neuroprotective Drugs Revenue by Application (2021-2026) & (US$ Million) Table 216. SAMEA Neuroprotective Drugs Revenue by Application (2027-2032) & (US$ Million) Table 217. SAMEA Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 218. SAMEA Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 219. SAMEA Neuroprotective Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 220. SAMEA Neuroprotective Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 221. SAMEA Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. SAMEA Neuroprotective Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. SAMEA Neuroprotective Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. SAMEA Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 225. SAMEA Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 226. SAMEA Neuroprotective Drugs Sales by Country (2027-2032) & (tons) Table 227. SAMEA Neuroprotective Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 228. SAMEA Neuroprotective Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 229. Brazil Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 230. Argentina Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 231. Chile Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 232. Colombia Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 233. Peru Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 234. Saudi Arabia Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 235. Israel Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 236. UAE Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 237. Turkey Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 238. Iran Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 239. Egypt Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Table 240. Key Raw Materials Table 241. Raw Materials Key Suppliers Table 242. Neuroprotective Drugs Distributors List Table 243. Neuroprotective Drugs Customers List Table 244. Research Programs/Design for This Report Table 245. Authors List of This Report Table 246. Secondary Sources Table 247. Primary Sources List of Figures Figure 1. Neuroprotective Drugs Image Figure 2. Global Neuroprotective Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cholinesterase inhibitors Image Figure 5. Anti-inflammatory Image Figure 6. Others Image Figure 7. Global Neuroprotective Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neuroprotective Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Alzheimer's disease Image Figure 10. Parkinson's disease Image Figure 11. Others Image Figure 12. Global Neuroprotective Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Neuroprotective Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Neuroprotective Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Neuroprotective Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Neuroprotective Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Neuroprotective Drugs Sales (2021-2032) & (tons) Figure 18. Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 19. Global Neuroprotective Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Neuroprotective Drugs Sales YoY (2021-2032) & (tons) Figure 21. Europe Neuroprotective Drugs Sales YoY (2021-2032) & (tons) Figure 22. China Neuroprotective Drugs Sales YoY (2021-2032) & (tons) Figure 23. Asia (Excluding China) Neuroprotective Drugs Sales YoY (2021-2032) & (tons) Figure 24. South America, Middle East and Africa Neuroprotective Drugs Sales YoY (2021-2032) & (tons) Figure 25. Global Neuroprotective Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Neuroprotective Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Neuroprotective Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Neuroprotective Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Neuroprotective Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Neuroprotective Drugs Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 32. Global Neuroprotective Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Neuroprotective Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Neuroprotective Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Neuroprotective Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Neuroprotective Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Neuroprotective Drugs Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 38. Global Neuroprotective Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Neuroprotective Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Neuroprotective Drugs Revenue Share by Type (2021-2032) Figure 41. North America Neuroprotective Drugs Sales Share by Type (2021-2032) Figure 42. North America Neuroprotective Drugs Revenue Share by Application (2021-2032) Figure 43. North America Neuroprotective Drugs Sales Share by Application (2021-2032) Figure 44. North America Neuroprotective Drugs Revenue Share by Country (2021-2032) Figure 45. North America Neuroprotective Drugs Sales Share by Country (2021-2032) Figure 46. Europe Neuroprotective Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Neuroprotective Drugs Sales Share by Type (2021-2032) Figure 48. Europe Neuroprotective Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Neuroprotective Drugs Sales Share by Application (2021-2032) Figure 50. Europe Neuroprotective Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Neuroprotective Drugs Sales Share by Country (2021-2032) Figure 52. China Neuroprotective Drugs Revenue Share by Type (2021-2032) Figure 53. China Neuroprotective Drugs Sales Share by Type (2021-2032) Figure 54. China Neuroprotective Drugs Revenue Share by Application (2021-2032) Figure 55. China Neuroprotective Drugs Sales Share by Application (2021-2032) Figure 56. Asia Neuroprotective Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Neuroprotective Drugs Sales Share by Type (2021-2032) Figure 58. Asia Neuroprotective Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Neuroprotective Drugs Sales Share by Application (2021-2032) Figure 60. Asia Neuroprotective Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Neuroprotective Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Neuroprotective Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Neuroprotective Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Neuroprotective Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Neuroprotective Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Neuroprotective Drugs Revenue Share by Country (2021-2032) Figure 67. SAMEA Neuroprotective Drugs Sales Share by Country (2021-2032) Figure 68. Neuroprotective Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Neuroprotective Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • Anti-inflammatory
  • Others
Applications
  • Alzheimer's disease
  • Parkinson's disease
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Biogen
  • AstraZeneca
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroprotective Drugs Market by Type
  3. 1.2.1 Global Neuroprotective Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cholinesterase inhibitors
  5. 1.2.3 Anti-inflammatory
  6. 1.2.4 Others
  7. 1.3 Neuroprotective Drugs Market by Application
  8. 1.3.1 Global Neuroprotective Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Alzheimer's disease
  10. 1.3.3 Parkinson's disease
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Neuroprotective Drugs Market Dynamics
  1. 2.1 Neuroprotective Drugs Industry Trends
  2. 2.2 Neuroprotective Drugs Industry Drivers
  3. 2.3 Neuroprotective Drugs Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neuroprotective Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neuroprotective Drugs Revenue by Region
  3. 3.2.1 Global Neuroprotective Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroprotective Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Neuroprotective Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Neuroprotective Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neuroprotective Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neuroprotective Drugs Sales by Region
  9. 3.4.1 Global Neuroprotective Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neuroprotective Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Neuroprotective Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Neuroprotective Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neuroprotective Drugs Revenue by Manufacturers
  2. 4.1.1 Global Neuroprotective Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neuroprotective Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neuroprotective Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroprotective Drugs Sales by Manufacturers
  6. 4.2.1 Global Neuroprotective Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neuroprotective Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neuroprotective Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neuroprotective Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neuroprotective Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neuroprotective Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neuroprotective Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Neuroprotective Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neuroprotective Drugs Market CR5 and HHI
  16. 4.8.2 2025 Neuroprotective Drugs Tier 1, Tier 2, and Tier 3
5 Neuroprotective Drugs Market by Type
  1. 5.1 Global Neuroprotective Drugs Revenue by Type
  2. 5.1.1 Global Neuroprotective Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neuroprotective Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neuroprotective Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neuroprotective Drugs Sales by Type
  6. 5.2.1 Global Neuroprotective Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Drugs Sales by Type (2021-2032) & (tons)
  8. 5.2.3 Global Neuroprotective Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neuroprotective Drugs Price by Type
6 Neuroprotective Drugs Market by Application
  1. 6.1 Global Neuroprotective Drugs Revenue by Application
  2. 6.1.1 Global Neuroprotective Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neuroprotective Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neuroprotective Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neuroprotective Drugs Sales by Application
  6. 6.2.1 Global Neuroprotective Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neuroprotective Drugs Sales by Application (2021-2032) & (tons)
  8. 6.2.3 Global Neuroprotective Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neuroprotective Drugs Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd
  2. 7.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Neuroprotective Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck KGaA
  14. 7.3.1 Merck KGaA Company Information
  15. 7.3.2 Merck KGaA Business Overview
  16. 7.3.3 Merck KGaA Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck KGaA Neuroprotective Drugs Product Portfolio
  18. 7.3.5 Merck KGaA Recent Developments
  19. 7.4 Biogen
  20. 7.4.1 Biogen Company Information
  21. 7.4.2 Biogen Business Overview
  22. 7.4.3 Biogen Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Biogen Neuroprotective Drugs Product Portfolio
  24. 7.4.5 Biogen Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Neuroprotective Drugs Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 NeuroVive Pharmaceutical
  32. 7.6.1 NeuroVive Pharmaceutical Company Information
  33. 7.6.2 NeuroVive Pharmaceutical Business Overview
  34. 7.6.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio
  36. 7.6.5 NeuroVive Pharmaceutical Recent Developments
  37. 7.7 Neuren Pharmaceuticals
  38. 7.7.1 Neuren Pharmaceuticals Company Information
  39. 7.7.2 Neuren Pharmaceuticals Business Overview
  40. 7.7.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio
  42. 7.7.5 Neuren Pharmaceuticals Recent Developments
  43. 7.8 Genervon Biopharmaceuticals
  44. 7.8.1 Genervon Biopharmaceuticals Company Information
  45. 7.8.2 Genervon Biopharmaceuticals Business Overview
  46. 7.8.3 Genervon Biopharmaceuticals Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio
  48. 7.8.5 Genervon Biopharmaceuticals Recent Developments
  49. 7.9 Ceregene
  50. 7.9.1 Ceregene Company Information
  51. 7.9.2 Ceregene Business Overview
  52. 7.9.3 Ceregene Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Ceregene Neuroprotective Drugs Product Portfolio
  54. 7.9.5 Ceregene Recent Developments
  55. 7.10 Bionure
  56. 7.10.1 Bionure Company Information
  57. 7.10.2 Bionure Business Overview
  58. 7.10.3 Bionure Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Bionure Neuroprotective Drugs Product Portfolio
  60. 7.10.5 Bionure Recent Developments
  61. 7.11 BHR Pharma
  62. 7.11.1 BHR Pharma Company Information
  63. 7.11.2 BHR Pharma Business Overview
  64. 7.11.3 BHR Pharma Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 BHR Pharma Neuroprotective Drugs Product Portfolio
  66. 7.11.5 BHR Pharma Recent Developments
  67. 7.12 Allon therapeutics
  68. 7.12.1 Allon therapeutics Company Information
  69. 7.12.2 Allon therapeutics Business Overview
  70. 7.12.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Allon therapeutics Neuroprotective Drugs Product Portfolio
  72. 7.12.5 Allon therapeutics Recent Developments
8 North America
  1. 8.1 North America Neuroprotective Drugs Market Size by Type
  2. 8.1.1 North America Neuroprotective Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Neuroprotective Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Neuroprotective Drugs Price by Type (2021-2032)
  5. 8.2 North America Neuroprotective Drugs Market Size by Application
  6. 8.2.1 North America Neuroprotective Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Neuroprotective Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Neuroprotective Drugs Price by Application (2021-2032)
  9. 8.3 North America Neuroprotective Drugs Market Size by Country
  10. 8.3.1 North America Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neuroprotective Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Neuroprotective Drugs Market Size by Type
  2. 9.1.1 Europe Neuroprotective Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neuroprotective Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Neuroprotective Drugs Price by Type (2021-2032)
  5. 9.2 Europe Neuroprotective Drugs Market Size by Application
  6. 9.2.1 Europe Neuroprotective Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neuroprotective Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Neuroprotective Drugs Price by Application (2021-2032)
  9. 9.3 Europe Neuroprotective Drugs Market Size by Country
  10. 9.3.1 Europe Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neuroprotective Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Neuroprotective Drugs Market Size by Type
  2. 10.1.1 China Neuroprotective Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Neuroprotective Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Neuroprotective Drugs Price by Type (2021-2032)
  5. 10.2 China Neuroprotective Drugs Market Size by Application
  6. 10.2.1 China Neuroprotective Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Neuroprotective Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Neuroprotective Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroprotective Drugs Market Size by Type
  2. 11.1.1 Asia Neuroprotective Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neuroprotective Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Neuroprotective Drugs Price by Type (2021-2032)
  5. 11.2 Asia Neuroprotective Drugs Market Size by Application
  6. 11.2.1 Asia Neuroprotective Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neuroprotective Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Neuroprotective Drugs Price by Application (2021-2032)
  9. 11.3 Asia Neuroprotective Drugs Market Size by Country
  10. 11.3.1 Asia Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neuroprotective Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroprotective Drugs Market Size by Type
  2. 12.1.1 SAMEA Neuroprotective Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neuroprotective Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neuroprotective Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Neuroprotective Drugs Market Size by Application
  6. 12.2.1 SAMEA Neuroprotective Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neuroprotective Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neuroprotective Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Neuroprotective Drugs Market Size by Country
  10. 12.3.1 SAMEA Neuroprotective Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neuroprotective Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neuroprotective Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neuroprotective Drugs Value Chain Analysis
  2. 13.1.1 Neuroprotective Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neuroprotective Drugs Production Mode & Process
  6. 13.2 Neuroprotective Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neuroprotective Drugs Distributors
  9. 13.2.3 Neuroprotective Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst